Earnings Call Summary | Streamline Health Solutions(STRM.US) Q3 2024 Earnings Conference
Earnings Call Summary | Streamline Health Solutions(STRM.US) Q3 2024 Earnings Conference
Net loss for Q3 FY2024 was $2.5 million, a reduction from a net loss of $11.9 million in Q3 FY2023, reflecting lower total revenues, higher interest expenses offset by reductions in SG&A and R&D expenses.The following is a summary of the Streamline Health Solutions, Inc. (STRM) Q3 2024 Earnings Call Transcript:
以下是Streamline Health Solutions, Inc. (STRM) 2024財年第3季度業績會錄音的摘要：
Financial Performance:
財務表現：
Streamline reported Q3 FY2024 revenue of $4.4 million, down from $6.1 million in Q3 FY2023, impacted by client non-renewals despite new SaaS contracts.
SaaS revenue for Q3 FY2024 was $2.9 million, comprising 66% of the total revenue.
Net loss for Q3 FY2024 was $2.5 million, a reduction from a net loss of $11.9 million in Q3 FY2023, reflecting lower total revenues, higher interest expenses offset by reductions in SG&A and R&D expenses.
Booked SaaS ACV as of October 31st, 2024, totaled $14.1 million, with $12 million implemented.
Streamline報告2024財年第3季度營業收入爲440萬，低於2023財年第3季度的610萬，這受到客戶不續約的影響，儘管簽署了新的SaaS-雲計算合同。
2024財年第3季度SaaS-雲計算營業收入爲290萬，佔總營業收入的66%。
2024財年第3季度淨虧損爲250萬，相較於2023財年第3季度的1190萬淨虧損有所減少，反映出總營業收入下降，利息支出增加，但受到銷售和一般管理費用及研發費用減少的抵消。
截至2024年10月31日，已記錄的SaaS-雲計算年度合同價值（ACV）總計爲1410萬，其中1200萬已經實施。
Business Progress:
業務進展：
Streamline launched a quality module for eValuator during Q3, expanding its service offerings.
Developed best practice manuals and enhanced client relationships through focused efforts and direct resources.
Streamline plans to achieve a $15.5 million SaaS ARR by first half of FY2025.
Streamline在第三季度推出了eValuator的質量模塊，擴展了其服務產品。
制定最佳實踐手冊，通過專注的努力和直接的資源增強客戶關係。
Streamline計劃在2025財年上半年實現1550萬SaaS-雲計算年經常性收入。
Opportunities:
機會：
The growth and implementation of the eValuator and RevID platforms, including the new quality module, bode well for expanding client relationships and penetrating new markets.
Plans to unlock significant value through displacement campaigns, partnerships, and leveraging existing client successes to gain new clients.
eValuator和RevID平台的增長和實施，包括新的質量模塊，對擴展客戶關係和進入新市場具有良好前景。
計劃通過置換活動、合作伙伴關係以及利用現有客戶的成功來獲得新客戶，從而解鎖顯著的價值。
Risks:
風險：
Lower total revenue impacted by non-renewals of client contracts posing a risk to anticipated growth and survival in a competitive sector.
Reliance on advancing new module developments and penetrating new markets amid economic and sector-specific challenges.
受到客戶合同未續簽影響，總營業收入下降，給預期的增長和在競爭激烈的板塊中生存帶來了風險。
在經濟和特定板塊挑戰中，依賴於推進新模塊開發和進入新市場。
More details: Streamline Health Solutions IR
更多詳情：Streamline Health Solutions IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更全面的細節，請參閱IR網站。 文章僅供投資者參考，不構成任何指導或推薦建議。
譯文內容由第三人軟體翻譯。
